Search Results
May 28, 2026, 12:00 ET DELFI Diagnostics Receives New York State Department of Health Clinical Laboratory Permit, Completing Authorization to Serve Health Systems Across All 50 States
blood, an approach known as fragmentomics, to help detect lung cancer with high sensitivity. FirstLook Lung, the first commercially available blood-based screening test for lung cancer in the United States, serves individuals eligible for lung cancer screening through a simple blood draw that integrates
More news about: DELFI Diagnostics
May 28, 2026, 11:15 ET Healthgrades Names Southern California Hospitals a 2026 Patient Safety Excellence Award™ Recipient
risk of experiencing these leading complications:In-hospital fall resulting in fracture (52.4% less likely)Collapsed lung due to a procedure in or around the chest (57.5% less likely)Catheter-related bloodstream infections acquired in the hospital (67.8% less likely)Pressure
More news about: Southern California Hospitals
May 28, 2026, 10:41 ET University of Chicago Urologist Performs First Commercial Vanquish® Water Vapor Ablation Procedures in the State
treatment for injuries or help managing chronic illnesses. We also offer on-site urgent aid, laboratory testing, X-rays, DEXA scans, screening mammography, lung cancer screening, stress tests and rehabilitation services.About Francis MedicalFrancis Medical is committed to developing urological
More news about: Francis Medical, Inc.
May 28, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
May 28, 2026, 09:15 ET Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, from 9:00 a.m. to 12:00 p.m. (abstract ID 8591, poster board #381, Lung Cancer: Non–Small Cell Metastatic track). More information can be found at
More news about: Illumina, Inc.
May 28, 2026, 09:15 ET Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
dose.To support a future biologics licensing application, Beam anticipates enrolling approximately 50 additional patients with AATD-associated lung disease in an expansion of the ongoing open-label trial, with the pivotal cohort expected to initiate in the second half of 2026. CEO John Evans, who
More news about: USA News Group
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.Bradley Monk, MDTroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan
More news about: Florida Cancer Specialists & Research Institute
May 28, 2026, 07:52 ET Brayton Purcell LLP Highlights KQED Investigation on California's Silicosis Crisis Linked to Artificial Stone
article describe lung transplantation as an extremely costly intervention that often extends life for only a limited period, underscoring the seriousness of advanced silicosis.Brayton Purcell LLP has represented individuals and families affected by asbestos exposure and occupational lung diseases, including
More news about: Brayton Purcell LLP
May 28, 2026, 05:49 ET LUNGevity Foundation Welcomes Early Detection Champion Dr. Michael Gieske to its Board of Directors
LUNGevity Foundation, a nonprofit dedicated to advancing lung cancer research, improving access to screening and treatment, and supporting people impacted by lung cancer, proudly announces the appointment of Dr. Michael Gieske, Director of Lung Cancer Screening at St. Elizabeth Healthcare, to its Board
More news about: LUNGevity Foundation
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), the world's most influential scientific meeting in the lung cancer field, taking place September 12–15, where Leads Biolabs
More news about: Nanjing Leads Biolabs Co., Ltd.
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
documents subsequently submitted to the Hong Kong Stock Exchange.For more information, please contact:Investor Contacts: Donald LungE-mail: [email protected] Contacts:Ariel
More news about: Antengene Corporation Limited
May 27, 2026, 18:00 ET FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test
screening test in asymptomatic adults aged 40 years and older to assist in the detection of cancers within the scope of the assay, including breast, lung, liver, colorectal, gastric, ovarian, pancreatic, esophageal, endometrial and head & neck cancers.The FDA grants Breakthrough Device Designation
More news about: GENE SOLUTIONS SGP PTE. LTD.
May 27, 2026, 13:44 ET Healthgrades Names Los Angeles Community Hospitals a 2026 Patient Safety Excellence Award™ Recipient
risk of experiencing these leading complications:In-hospital fall resulting in fracture (52.4% less likely)Collapsed lung due to a procedure in or around the chest (57.5% less likely)Catheter-related bloodstream infections acquired in the hospital (67.8% less likely)Pressure
More news about: Los Angeles Community Hospitals
May 27, 2026, 09:05 ET Children's Hospital Colorado Leads Nation in Treatment for Cystic Fibrosis Before Birth
in early infancy supports healthier cell function during a critical window of lung development. Babies exposed during this period have shown lower‑than‑expected sweat chloride levels — a well-established marker linked to lung health. Continuing treatment after birth may help preserve those gains during
More news about: Children's Hospital Colorado
May 27, 2026, 09:00 ET IMMP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Immutep Limited Securities Lawsuit - Contact Levi & Korsinsky
Immutep Projected TACTI-004 Would Deliver a "New Standard of Care" for Lung Cancer Patients. Instead, the Trial Was Stopped for Futility After Enrolling Just Half Its Target, and IMMP Investors Lost $2.28 Per Share.NEW YORK, May
More news about: Levi & Korsinsky, LLP
May 27, 2026, 08:17 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
France.Breakthrough Finger-Prick Detection of Nucleosomes: Expanding global market potential for sepsis testing using lateral flow.European Lung Cancer Reimbursement: Formal reimbursement submission in France remains on schedule, with routine clinical use expected by end of 2026.Capture-Seq™
More news about: VolitionRx Limited
May 27, 2026, 08:00 ET Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
eight months of treatment."Having navigated the lung cancer journey as a caregiver and patient advocate, I know the deep impact this disease can have on quality of life," said Danielle Hicks, Chief Patient Officer for GO2 for Lung Cancer. "Patients with ROS1+ NSCLC tend to be younger, often
More news about: Nuvation Bio Inc.
May 27, 2026, 07:36 ET "This Product Has Truly Been Such A Blessing For My Health!" Gundry MD MCT Wellness, A Fat-Burning, Energy-Boosting Solution, Ideal For National Senior Health & Fitness Day
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 30 years helping people restore
More news about: Gundry MD
May 27, 2026, 07:27 ET Brayton Purcell LLP Highlights Sky News UK Investigation on California Artificial Stone Silicosis Crisis
The report presents a deeply human portrait of individuals living with advanced lung disease caused by inhalation of dust released during artificial stone fabrication. Artificial stone contains at least 90 percent crystalline silica,
More news about: Brayton Purcell LLP
May 27, 2026, 07:00 ET Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering,
More news about: Insmed Incorporated
May 27, 2026, 06:40 ET Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
Drug Application (NDA) for ZEGFROVY® (sunvozertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).
More news about: Dizal Pharmaceutical
May 27, 2026, 06:30 ET Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
NDA for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor (TKI) pre-treated advanced ALK-positive non-small cell lung cancer (NSCLC). The application has been granted Priority Review and assigned a PDUFA target action date of November 27, 2026.The submission
More news about: Nuvalent, Inc.
May 27, 2026, 05:38 ET Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List
HLX43, a potential best-in-class broad-spectrum anti-tumor PD-L1 ADC, will have its key subgroup progression-free survival (PFS) data in non-small cell lung cancer (NSCLC) presented for the first time in a Rapid Oral Presentation at ASCO, further supporting its clinical potential and value in the later-line
More news about: Fosun
May 27, 2026, 04:43 ET Foresee Pharmaceuticals Announces Completion of Casppian Phase 3 Study with Last Patient Last Visit and Confirms Topline Results: 94% of Patients Achieve LH Suppression with 6-Month Dosing Interval of Leuprolide Mesylate, also the acceptance of Casppian Study for Presentation at Endocrine Society, ENDO 2026 Medical Conference, as a Potential New Six-Month Treatment Option for Central Precocious Puberty
oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients was initiated in the second quarter of 2025. www.foreseepharma.com
More news about: Foresee Pharmaceuticals Co., Ltd.
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
Real-world outcomes of amivantamab monotherapy in advanced EGFR-mutant non-small cell lung cancer.
More news about: Hackensack Meridian John Theurer Cancer Center